TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02918292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin (ATG)
Description: Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI is to be delivered in a single dose of 200 cGy on Day -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haplo HSCT
Description: Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.
Study: NCT02272153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Refined grain
Study: NCT02826577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone 175mg
Description: Single Dose 175mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone 400mg
Description: Single Dose 400mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose
Study: NCT01273714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroid resection
Description: bilateral subtotal versus total thyroidectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroid resection
Description: bilateral subtotal versus total thyroidectomy
Study: NCT04609709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Manipulation, Electric Dry Needling and Exercise
Description: Thrust Manipulation, Electric Dry Needling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
Description: Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
Study: NCT03539185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope Airtraq
Description: Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscope
Description: Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
Study: NCT01438372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Description: Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ferrous sulfate
Description: Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
Study: NCT01173419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VNUS RF ClosureFAST
Description: VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VenaCure EVLT NeverTouch
Description: Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
Study: NCT04146623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-H1N1 influenza vaccine
Description: CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10\^5 plaque forming units (PFU).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Saline (0.9%) administered intranasally via sprayer
Study: NCT02561663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NWT-03, an egg-white protein hydrolysate
Description: egg-white protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NWT-03, an egg-white protein hydrolysate
Description: egg-white protein hydrolysate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02003261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol with Treatment As Usual
Description: Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
Study: NCT02766452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: You and your child in the recovery room DVD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard pre-operative preparation
Description: Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard pre-operative preparation
Description: Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
Study: NCT03790618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: Participants will be given 0.75mg/kg of 1.5mg/kg MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: Participants will be given 0.75mg/kg of 1.5mg/kg MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: Participants will be given 0.75mg/kg of 1.5mg/kg MDMA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3,4-Methylenedioxymethamphetamine
Description: Participants will be given 0.75mg/kg of 1.5mg/kg MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: Please see above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: Please see above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: Please see above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methamphetamine
Description: Please see above.
Study: NCT01713894

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid

Intervention type: OTHER
Group type: OTHER
Intervention: Standard
Study: NCT00481767

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervarix
Description: The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Al(OH)3
Description: Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
Study: NCT00840593

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical group
Description: The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical group
Description: The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
Study: NCT04012424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf
Description: effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf
Description: effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400mg starch
Description: patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 400mg starch
Description: patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
Study: NCT04365478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy
Description: rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
Study: NCT03601741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Antimicrobial Stethoscope Diaphragm Cover
Description: Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Antimicrobial Stethoscope Diaphragm Cover
Description: Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Stethoscopes
Description: Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Stethoscopes
Description: Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
Study: NCT02719834

Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.

Intervention type: DRUG
Intervention: Acetaminophen
Description: Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.

Intervention type: OTHER
Intervention: Placebo
Description: The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.

Intervention type: OTHER
Intervention: Placebo
Description: The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
Study: NCT03373461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 5, 25, 100 mg capsles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 5, 25, 100 mg capsles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 5, 25, 100 mg capsles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 5, 25, 100 mg capsles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to LNP023
Study: NCT03246841

Intervention type: OTHER
Group type: OTHER
Intervention: Genetic testing
Description: A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
Study: NCT00667797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol HCl
Description: Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol Sulfate
Description: Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
Study: NCT04182438

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low potassium content vegetables
Description: use low-potassium content vegetables

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low potassium content vegetables
Description: use low-potassium content vegetables
Study: NCT02846870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visually enhanced prostate cancer educational presentation
Description: Receive visually enhanced prostate cancer educational presentation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard prostate cancer education presentation
Description: Receive standard prostate cancer education presentation
Study: NCT00323037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol controlled release
Description: Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol immediate release
Description: Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
Study: NCT04813913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV
Description: Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
Study: NCT03152994

Intervention type: OTHER
Intervention: Checking fasting blood glucose(FBG)
Description: This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.

Intervention type: OTHER
Intervention: Checking fasting blood glucose(FBG)
Description: This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
Study: NCT03769194

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15
Description: a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15
Description: a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA15
Description: a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: PBS (Phosphate Buffered Saline)
Study: NCT02652598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Study: NCT04508114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted Index
Description: The participant will be informed the ATP testing result and explanation in pretest.
Study: NCT01507714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preventive transobturator tension free vaginal tape
Description: during the vaginal wall repair surgery, a TVT-O procedure will be done
Study: NCT03766893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy maintenance addiction care
Description: Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
Study: NCT00203905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab
Description: Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil, Hydroxyurea-[FHX]
Description: Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
Study: NCT02950935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
Study: NCT03854240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic block (Group C) and modified block (Group M) groups
Description: Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic block (Group C) and modified block (Group M) groups
Description: Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
Study: NCT02348320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized polyepitope DNA vaccine
Study: NCT01368211

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-4-day-old Mirasol-treated Platelets Transfusion
Description: 2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-4-day-old Mirasol-treated Platelets Transfusion
Description: 2-4-day-old Mirasol-treated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-4-day-old Untreated Platelets Transfusion
Description: 2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-4-day-old Untreated Platelets Transfusion
Description: 2-4-day-old Untreated Platelets Units with:~* Platelet yield between 2.4x10e11 and 4.5x10e11~* Plasma carryover of \>32%~* Cell count \> 800x103/µL
Study: NCT03087331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reviews, assessment, recommendations, education.